Keudell Morrison Wealth Management Makes New $1.97 Million Investment in Gilead Sciences, Inc. $GILD

Keudell Morrison Wealth Management bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,022 shares of the biopharmaceutical company’s stock, valued at approximately $1,967,000.

Several other hedge funds have also recently modified their holdings of GILD. Massachusetts Financial Services Co. MA increased its stake in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares during the last quarter. Invesco Ltd. increased its stake in shares of Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $133,049,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead Sciences from hold to buy and set a $165 price target, signaling confidence in upside from current levels.
• Positive Sentiment: Gilead completed its acquisition of Tubulis GmbH, adding next-generation ADC assets and strengthening its oncology pipeline, which could support longer-term growth.
• Positive Sentiment: Gilead and Kite highlighted momentum in oncology ahead of ASCO and EHA 2026, with more than 25 abstracts and six oral presentations showcasing progress across antibody-drug conjugates and cell therapy.
• Positive Sentiment: Zacks Research raised its Q1 2028 EPS estimate for Gilead to $2.21 from $2.15, suggesting stronger long-term earnings expectations. Article source
• Positive Sentiment: Gilead also renewed its collaboration with the World Health Organization to help eliminate visceral leishmaniasis, reinforcing its global health profile and brand reputation.
• Neutral Sentiment: Zacks Research made a series of small estimate adjustments for future periods, including modest cuts to Q4 2026, Q2 2027, Q3 2027, FY2027, and FY2028 earnings, which signals some caution but not a major shift in the long-term thesis. Article source
• Negative Sentiment: Zacks Research lowered several near- to medium-term EPS estimates, including Q4 2026 to $2.07, Q2 2027 to $2.14, Q3 2027 to $2.35, FY2027 to $9.11, and FY2028 to $10.00, which may weigh on sentiment around earnings growth expectations.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday. Royal Bank Of Canada decreased their price target on shares of Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a research note on Friday, May 8th. UBS Group raised their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Wolfe Research raised their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Stock Down 0.1%

Gilead Sciences stock opened at $130.50 on Friday. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The firm has a market capitalization of $162.02 billion, a price-to-earnings ratio of 17.78 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a 50 day simple moving average of $136.50 and a 200 day simple moving average of $133.64.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the business earned $1.81 EPS. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 63,000 shares of company stock worth $8,523,570. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.